U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07560449) titled 'QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms' on April 21.
Brief Summary: The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Malignant Plasma Cell Neoplasms
Intervention:
DRUG: QLS4131
QLS4131 will be administered subcutaneously.
DRUG: QL2109
QL2109 will be administered subcutaneously.
DRUG: Pomalid...